8-KAcquisitions & DispositionsRegulation FDExhibits & Filings

Elevance Health, Inc. 8-K Report, Acquisition Completed (Dec 1, 2009)

Filed December 1, 2009For Securities:ELV

Summary

Elevance Health, Inc. (formerly WellPoint, Inc.) announced on December 1, 2009, the completion of the sale of its NextRx subsidiaries to Express Scripts, Inc. (ESI) for $4.675 billion in cash. This significant divestiture is a strategic move aimed at streamlining operations and focusing on core health benefits businesses. The transaction included the sale of multiple subsidiary entities that housed the NextRx operations. Concurrent with the sale, Elevance Health entered into a long-term, ten-year Pharmacy Benefit Management (PBM) Services Agreement with ESI, designating ESI as the exclusive provider for a comprehensive suite of PBM services. This includes pharmacy network management, claims processing, rebate management, and drug utilization oversight. Investors should note the contractual obligations, including minimum volume requirements and performance standards, which carry potential financial penalties for non-compliance. The company also updated its full-year 2009 earnings per share guidance to reflect the impact of this transaction.

Key Highlights

  • 1Completion of the sale of NextRx subsidiaries to Express Scripts, Inc. for $4.675 billion in cash.
  • 2The sale involved multiple wholly-owned subsidiaries engaged in pharmacy benefit management operations.
  • 3Execution of a long-term, ten-year Pharmacy Benefit Management (PBM) Services Agreement with Express Scripts.
  • 4ESI is appointed as the exclusive PBM services provider for Elevance Health under the new agreement.
  • 5The PBM agreement covers a broad range of services including network management, claims processing, and drug utilization.
  • 6The agreement includes minimum volume requirements and performance standards with potential financial penalties.
  • 7Updated full-year 2009 EPS guidance reflects the impact of the divestiture and associated charges.

Frequently Asked Questions

This 8-K filing primarily announced the completion of the sale of WellPoint's (now Elevance Health) NextRx subsidiaries to Express Scripts, Inc. and the entry into a long-term Pharmacy Benefit Management (PBM) Services Agreement with Express Scripts.

WellPoint received $4.675 billion in cash from the sale, subject to adjustments. The company also updated its full-year 2009 EPS guidance to reflect an estimated net gain of $4.34 per share from this sale, along with other previously reported charges.

The agreement establishes Express Scripts as the exclusive provider of certain pharmacy benefit management services for a ten-year period. Key services include pharmacy network management, claims processing, rebate management, and drug utilization oversight. The contract also includes minimum volume commitments and performance standards that, if not met, could lead to financial penalties or termination.

The sale signifies a strategic divestiture of WellPoint's PBM operations, allowing the company to focus on its core health benefits business. The long-term PBM agreement ensures continued access to these essential services through an exclusive partnership with Express Scripts, albeit with contractual obligations and potential financial implications based on performance and volume.